newsfilter
← Latest News
Business Wire·

Infinity Pharmaceuticals Provides MARIO-3 Update in Patients with Front Line Metastatic Triple Negative Breast Cancer Suggesting Potential Long-Term Patient Benefit of Eganelisib

–Encouraging one-year progression free survival rates in MARIO-3 1L TNBC study regardless of PD-L1 status– - 52% increase in one-year progression free survival rate in ITT patient population compared to IMpassion130